Ads
related to: abbvie pharmaceuticals- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- AbbVie News Center
See Our Achievements, Growth Story,
and More Today.
- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Read AbbVie Stories
Search results
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 8 hours agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition By Investing.com
Investing.com· 6 hours agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
Barclays lowers AbbVie shares target on Humira sales erosion concerns By Investing.com
Investing.com· 14 hours ago:ABBV) shares, reducing the price target to $187 from the previous $195. The revision was attributed...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 3 days agoThose sales figures would be more than twice the drugs' totals last year. Those are just two of the...
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 3 days agoAbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 4 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 2 days agoLast year, the company earned approval for Epkinly, a new cancer medicine that could reach peak sales of $3 billion in the U.S. alone, according to some...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 4 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
GuruFocus.com via Yahoo Finance· 3 days agoOn April 26, 2024, AbbVie Inc (NYSE:ABBV) released its 8-K filing, detailing the financial outcomes...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 3 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
Ad
related to: abbvie pharmaceuticals